{
    "title": "Boost for Glaxo as pharma giant hails 'truly exceptional' results in key respiratory virus vaccine trial",
    "url": "https://www.dailymail.co.uk/money/markets/article-11313029/Glaxo-hails-truly-exceptional-results-respiratory-virus-vaccine-trial.html",
    "date": "2022-10-13",
    "keywords": [
        "vaccine",
        "rsv",
        "cent",
        "jab",
        "gsk",
        "trial",
        "disease",
        "share",
        "fund",
        "drug",
        "year",
        "phase",
        "study",
        "reduction",
        "version",
        "risk",
        "pfizer",
        "trade",
        "money",
        "diy",
        "platform",
        "capital",
        "zantac",
        "johnson",
        "investment",
        "account",
        "fee",
        "win",
        "pipeline",
        "virus",
        "rsvrsv",
        "coldlike",
        "cause",
        "pneumonia",
        "causing",
        "iii",
        "diseasea",
        "effectiveness",
        "boost",
        "executive",
        "emma",
        "today",
        "research",
        "wood",
        "officer",
        "burden",
        "illness",
        "august",
        "sizzling",
        "sun",
        "cream",
        "push",
        "relief",
        "mortgage",
        "sterling",
        "partner",
        "article",
        "end",
        "approval",
        "world",
        "newssusie",
        "jana",
        "analyst",
        "broker",
        "shore",
        "stock",
        "price",
        "performance",
        "investor",
        "liability",
        "lawsuit",
        "chemicalthe",
        "incident",
        "pharma",
        "damagesaside",
        "battle",
        "position",
        "race",
        "moderna",
        "group",
        "isa",
        "month",
        "community",
        "model",
        "affiliate",
        "product",
        "commission",
        "editorial",
        "independence",
        "investing"
    ],
    "category": [
        "money",
        "markets"
    ]
}